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Tigecycline Resistance Can Occur Independently of the ramA Gene in
Klebsiella pneumoniae
Mark Veleba and Thamarai Schneiders
Centre for Infection and Immunity, Queen’s University Belfast, Medical Biology Centre, Belfast, United Kingdom
Tigecycline resistance in Klebsiella pneumoniae results from ramA upregulation that causes the overexpression of the efflux
pump, AcrAB-TolC. Tigecycline mutants, derived from Ecl8ramA, can exhibit a multidrug resistance phenotype due to in-
creased transcription of themarA, rarA, acrAB, and oqxAB genes. These findings support the idea that tigecycline or multidrug
resistance in K. pneumoniae, first, is not solely dependent on the ramA gene, and second, can arise via alternative regulatory
pathways in K. pneumoniae.
Tigecycline resistance in Klebsiella pneumoniae is on the in-crease, with reported cases in Greece (9), India (3), and Saudi
Arabia (1), and its effectiveness as a therapeutic agent is uncertain,
with patients treated with tigecycline showing persistent bactere-
mia caused by Escherichia coli, Acinetobacter baumanii, and K.
pneumoniae (2).
The AcrAB-TolC pump complex is a clinically relevant efflux
system activated by several AraC-type transcriptional regulators
such as MarA, SoxS, and RamA (7). Genetic studies have shown
that resistance to tigecycline is mediated by the increased expres-
sion of the ramA gene, which subsequently results in the upregu-
lation of the efflux pump acrAB in K. pneumoniae (10, 11) and
Enterobacter cloacae (6). It has been shown that the increased ex-
pression of the ramA gene is linked to mutations within the cog-
nate repressor, ramR, that is divergently transcribed from the
romA-ramA genes (10). However, in a recent study (10), it was
shown that high-level tigecycline resistance is exhibited in clinical
strains of K. pneumoniae that do not overexpress ramA or acrAB;
hence, we hypothesized that alternative pathways to tigecycline
resistance must exist in K. pneumoniae. Accordingly, we searched
the Klebsiella genome for AraC-type transcriptional regulators
that had a size similar to those of the other multidrug resistance
regulators such asmarA, soxS, and ramA. The bioinformatic anal-
yses of the genome of KlebsiellaMGH78578 (NC_09648) located
an additional regulator, which we have termed rarA (Fig. 1). In an
accompanying paper, we report the characterization of this novel
multidrug-resistant (MDR) regulator (13), which, when overex-
pressed, exhibits a MDR phenotype independently ofmarA-soxS-
rob and ramA. In K. pneumoniae and Enterobacter spp., the chro-
mosomally encoded rarA regulator lies downstream of the efflux
pump, oqxAB (Fig. 1), which has been previously linked to de-
creased susceptibility to olaquindox, ciprofloxacin, and chloram-
phenicol (5). Interestingly, in E. coli, the gene locus encoding the
efflux pumphas been shown to be located on the pOLA52 plasmid
in strains isolated frompigmanure (12), where the locus is flanked
by two IS26 insertion sequences, highly suggestive of its genetic
mobility.
Our research issue was whether alternative pathways to tigecy-
cline resistance exist in K. pneumoniae. Accordingly, we used a
genetically modified Klebsiella pneumoniae Ecl8ramA strain,
with amarkerless deletion of the ramA gene, in a tigecycline selec-
tion experiment. The markerless deletion of the ramA gene was
constructed as described previously (8). Briefly, Ecl8ramA from
an overnight culture was grown overnight at 37°C on agar plates
containing tigecycline concentrations of 0.5 g/ml, 1 g/ml, 2
g/ml, 4 g/ml, and 8 g/ml. The overnight culture was also
diluted in phosphate-buffered saline (PBS) and grown on LB
plates without antibiotic to establish baseline growth levels. After
overnight incubation, we picked three mutants (TGC1-3) from
the plate with 4g/ml for further analyses. Accordingly, we found
that the mutational frequency of Ecl8ramA with respect to tige-
cycline was 0.466 106.MIC testing (performed in triplicate) of
tigecycline, ciprofloxacin, norfloxacin, tetracycline, and olaquin-
dox was undertaken as described in the British Society for Anti-
microbial Chemotherapy (BSAC) guidelines (4). Additionally,
quantitative real-time PCR analyses were carried out to assess ex-
pression levels of genes rarA, oqxB, acrA, marA, and soxS in the 3
mutant strains by the use of cDNA (generated by AffinityScript
[Agilent]) and a Brilliant III kit (Agilent) for amplification. Exper-
iments were conducted using a Stratagene Mx3005P system (Agi-
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FIG 1 Organization of rarA locus in K. pneumoniae. This genomic organization is conserved in Enterobacter sp. 638, Serratia proteamaculans 568, and
Enterobacter cloacae.
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lent) and analyzed using MxPro software (Agilent). MIC suscep-
tibility testing demonstrated that all 3 clones exhibited reduced
susceptibility to the antibiotics tested in comparison to the paren-
tal strain, Ecl8ramA (see Table 1). We also found that the tran-
scriptional levels of rarA (4.59-fold, 17.15-fold, and 2.14-fold, re-
spectively) andmarA (6.06-fold, 12.13-fold, and 5.28-fold) as well
as those of the efflux operons oqxAB (6.06-fold, 13.93-fold, and
3.03-fold) and acrAB (55.72-fold, 103.97-fold, and 27.86-fold)
were higher than the expression levels seenwith the parental strain
(Ecl8ramA) (see Table 1). Of note, soxS levels were found to be
unaltered in comparison to those seen with the parental strain
(Ecl8ramA).
Our work shows that tigecycline exposure to Ecl8ramA can
generate mutants that exhibit low-level multidrug resistance.
However, in order to pinpoint the individual contributions of
rarA, marA, and oqxAB, individual gene deletions are essential.
We surmise that both rarA andmarAprovide alternative pathways
for the emergence of multidrug resistance inK. pneumoniae in the
absence of the ramA gene. Additionally, we demonstrate that both
the acrAB and the newly described oqxAB efflux pump can con-
tribute to the MDR phenotype. From our findings, it is evident
that a functioning ramA gene is not always needed to confer tige-
cycline resistance in K. pneumoniae.
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TABLE 1MIC and QPCR measurements of tigecycline mutants (TGC1, TGC3, and TGC5)
Strain
MICa Fold expression increase vs Ecl8ramA
NOR CIP TET OQX TIG rarA oqxA marA acrB
Ecl8 0.250 0.031 4 16 2
Ecl8ramA 0.063 0.016 2 8 1
TGC1 8 0.25 16 32 16 4.59 6.06 6.06 55.72
TGC3 8 0.25 8 32 8 17.15 13.93 12.13 103.97
TGC5 8 0.25 8 16 8 2.14 3.03 5.28 27.86
a NOR, norfloxacin; CIP, ciprofloxacin; TET, tetracycline; OQX, olaquindox; TIG, tigecyline.
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